Brain

Q2 2024 Revenue and Business Highlights, Guidance Upgrade

MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update…

6 months ago

Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease

The project will evaluate the real-world impact of Brainomix's e-Lung imaging software to improve the identification and access to treatment for…

6 months ago

BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards

Recognized for excellence in writing, news, mental health, financial/investment and economics categories LONDON, July 18, 2024 /PRNewswire/ -- BioWorld™ published…

6 months ago

AI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034: Global Surge in AI Start-up Funding Expands Diagnostic Systems Integration | TMR

AI-powered diagnostic systems deliver precise and efficient diagnoses, enabling healthcare professionals to develop timely and effective treatment plans. This integration…

6 months ago

Cumulus Neuroscience to Present Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference

Full analysis of first-in-class CNS-101 study measuring functional neurophysiology at home in patients living with mild Alzheimer's dementiaPoster presentations scheduled for the…

6 months ago

Hyperfine Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-in-Class Ultra-Low-Field Brain Images

The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list.GUILFORD,…

6 months ago

Hyperfine Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-in-Class Ultra-Low-Field Brain Images

The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list.GUILFORD,…

6 months ago

CervoMed to Participate in the Emerging Growth Conference

BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for…

6 months ago

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024

Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) --…

6 months ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had…

6 months ago